Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 17/20 | 0.58 |
| ▸ | MMP12 | P39900 | 5/20 | 0.58 |
| ▸ | MMP14 | P50281 | 8/20 | 0.47 |
| ▸ | MMP2 | P08253 | 4/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6036011 | 0.90 | MMP13 (0.55) | MMP13MMP12MMP14MMP2KCNH2 | |
| SCHEMBL6035791 | 0.90 | MMP13 (0.53) | MMP13MMP12MMP14MMP2 | |
| SCHEMBL6036629 | 0.90 | TP53 (0.53) | MMP13MMP12MMP14MMP2EPHX2 | |
| SCHEMBL6948792 | 0.87 | MMP13 (0.56) | MMP13MMP12MMP14MMP2FPR2 | |
| SCHEMBL6943119 | 0.84 | MMP13 (0.52) | MMP13MMP12MMP14MMP2FPR2 | |
| SCHEMBL6097841 | 0.83 | MMP13 (0.49) | MMP13MMP12MMP14MMP2FPR2 | |
| SCHEMBL6036512 | 0.80 | MMP2 (0.51) | MMP13MMP14MMP2EPHX2 | |
| SCHEMBL6096540 | 0.79 | MMP13 (0.57) | MMP13MMP12MMP14MMP2FPR2 | |
| SCHEMBL6099484 | 0.77 | MMP13 (0.49) | MMP13MMP12MMP14MMP2FPR2 | |
| SCHEMBL6094794 | 0.77 | MMP13 (0.58) | MMP13MMP12MMP14MMP2FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7015234-B2 | Hydroxamic acid derivatives | CELLTECH R & D LIMITED (GB) | 2006-03-21 | — | — | US | disclosed |
| EP-1414812-B1 | HYDROXAMIC ACID DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-02-22 | — | — | EP | disclosed |
| US-20040192733-A1 | Hydroxamic acid derivatives | UCB PHARMA S.A. (BE) | 2004-09-30 | — | — | US | disclosed |
| EP-1414812-A1 | HYDROXAMIC ACID DERIVATIVES | Celltech R & D Limited (GB) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003014101-A1 | HYDROXAMIC ACID DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192733-A1 | Hydroxamic acid derivatives | MMP1, MMP3, MMP13 | MMP13 3/4885MMP12 31/4885MMP14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.